Related Experiment Video
Updated: Jun 18, 2025
00:06
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective
Junjun Jia1, Chenyuan Ding2, Mengjie Mao3
1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, China.
BMC Gastroenterology
|July 30, 2024
Summary
Conversion therapy followed by surgery offers a promising treatment for unresectable hepatocellular carcinoma, yielding good overall survival and recurrence-free survival rates in patients achieving pathological complete response.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) presents a significant global health challenge, particularly in China, with high mortality rates.
- Unresectable HCC often carries a poor prognosis, necessitating novel therapeutic strategies.
- Conversion therapy aims to improve outcomes for patients with initially unresectable liver cancer.
Purpose of the Study:
- To evaluate the efficacy of conversion therapy followed by surgical resection in patients with initially unresectable HCC.
- To assess overall survival (OS) and recurrence-free survival (RFS) rates in this patient cohort.
- To investigate prognostic factors influencing survival outcomes after conversion therapy.
Main Methods:
- Retrospective analysis of 60 patients (18-75 years) with unresectable HCC who underwent conversion therapy and subsequent surgery.
- Pathological assessment for complete tumor necrosis post-surgery.
- Data collected from January 2019 to December 2021 at the First Affiliated Hospital, Zhejiang University School of Medicine.
Main Results:
- High survival rates observed: 1-year OS 98.3%, 3-year OS 95.6%.
- Encouraging recurrence-free survival: 1-year RFS 81.1%, 3-year RFS 71.4%.
- No significant difference in RFS based on BCLC stage or use of postoperative adjuvant therapy.
Conclusions:
- Conversion therapy followed by surgical resection is a viable and promising treatment for initially unresectable HCC.
- Achieving a pathological complete response is associated with favorable patient prognosis.
- This approach offers a potential pathway to improved survival for advanced HCC patients.
